WSSAAI 2022 Northwest Allergy Forum
The Northwest Allergy Forum is a CME educational meeting jointly provided by the American College of Allergy, Asthma & Immunology and the Oregon and Washington Societies of Allergy, Asthma & Immunology. The program is a two-day event with speakers covering a range of topics such as asthma, eczema, food allergy, vocal cord dysfunction and research developments.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Washington State Society of Allergy, Asthma & Immunology (WSSAAI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 8 contact hours.
This activity is supported in part by independent medical education grants from Grifols, Biocryst, CSL Behring and Aimmune.
Allied health professionals
Upon completion of this activity the participant should be able to:
1. Identify the most effective medical treatments for CRS
2. Assess the benefits and limitations of the available treatments for HAE
3. Use clinical, laboratory, and genetic features to formulate a treatment regimen for CVID that addresses both immune deficiency and immune dysregulation features of the disease.
4. Identify advantages and disadvantages of all methods of food allergy treatment
All identified relevant financial relationships have been mitigated.
Lori Broderick, MD
Kevin Cook, MD
Advisor: ALK, Sanofi
Stephanie Leonard, MD
Speaker: Aimmune Therapeutics, DBV Technologies, Cour Pharmaceuticals Development Co., Inc.
Advisor: Aimmune Therapeutics
Marc Riedl, MD, MS
Consultant: Astria, BioCryst, Biomarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, Ipsen, KalVista, Pfizer, Pharming, Pharvaris, RegenexBio, Sanofi-Regeneron, Takeda
Research Support: BioCryst, Biomarin, CSL Behring, Ionis, KalVista, Pharvaris, Takeda
Speaker: CSL Behring, Grifols, Pharming, Takeda
Troy Torgerson, MD, PhD
Advisor: Pharming Healthcare, Takeda
Consultant: Horizon Therapeutics, Takeda
Dan Petroni, MD
Consultant: Jubilant Hollister-Stier, Takeda
Ted Song, DO
Speaker: AstraZeneca, Boehringer -Ingelheim
The following have no relevant financial relationships to disclose:
Ian M. Humphreys, DO, FARS
Ian A. Myles, MD, MPH
Mark LaShell, MD
Mark Tucker, MD
Mary Lasley, MD
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:
Ambulatory procedure centers
- Blood banks
- Diagnostic labs that do not sell proprietary products
- Electronic health records companies
- Government or military agencies
- Group medical practices
- Health law firms
- Health profession membership organizations
- Hospitals or healthcare delivery systems
- Infusion centers
- Insurance or managed care companies
- Nursing homes
- Pharmacies that do not manufacture proprietary compounds
- Publishing or education companies
- Rehabilitation centers
- Schools of medicine or health science universities
- Software or game developers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated
- 8.00 AMA PRA Category 1 Credit™
- 8.00 Attendance
- 8.00 CBRN